Recurrent meningioma

Chamberlain, Marc C.; Glantz, Michael; Fadul, Camilo E.

doi:10.1212/01.wnl.0000271382.62776.b7

Cited by 182 publications

(154 citation statements)

References 13 publications

Supporting

Mentioning

140

Contrasting

Unclassified

Order By: Relevance

“…5,13 A pilot study of sustained-release somatostatin (octreotide acetate) for the treatment of patients with refractory meningiomas (of all World Health Organization [WHO] grades) indentified 3 of 16 (18.8%) patients with octreotidepositive pulmonary lesions. 14 In the current study, 6 cases of metastatic meningioma are presented in which pulmonary meningioma metastases were detected after 111 In-octreotide scintigraphy and in 1 of the cases, meningioma histology was confirmed by surgical resection and pathology analysis.…”

mentioning

confidence: 80%

“…2,14,22 However, in patients with histologically atypical (WHO grade II) or anaplastic (WHO grade III) tumors, these treatment approaches are almost never curative, with 10-year disease-free survival rates of 13% and 0%, respectively. 14,22 In these patients, treatment with doxorubicin, hydroxyurea, temozolomide, irinotecan, interferon-a, tamoxifen, imatinib, mifepristone, or octreotide acetate have been attempted. 14,22 One study reported that octreotide acetate was found to increase the progression-free survival rate at 6 months to 44% in patients with recurrent meningiomas that expressed somatostatin receptors.…”

Section: Discussionmentioning

confidence: 99%

“…14,22 In these patients, treatment with doxorubicin, hydroxyurea, temozolomide, irinotecan, interferon-a, tamoxifen, imatinib, mifepristone, or octreotide acetate have been attempted. 14,22 One study reported that octreotide acetate was found to increase the progression-free survival rate at 6 months to 44% in patients with recurrent meningiomas that expressed somatostatin receptors. 14 Correlating the histologic features of meningiomas with the potential for metastatic behavior has been an important topic of study because patient prognosis and future treatment options depend critically on tumor behavior.…”

Section: Discussionmentioning

confidence: 99%

“…14,22 One study reported that octreotide acetate was found to increase the progression-free survival rate at 6 months to 44% in patients with recurrent meningiomas that expressed somatostatin receptors. 14 Correlating the histologic features of meningiomas with the potential for metastatic behavior has been an important topic of study because patient prognosis and future treatment options depend critically on tumor behavior. Many criteria have been used to define malignancy in meningioma.…”

Section: Discussionmentioning

confidence: 99%

“…We sought to determine radiographic response (using the modified criteria of Macdonald et al 15 ) and the overall survival (OS) of these patients from the time of the positive 111 In-octreotide scintigraphy, and to compare their survival with historical control data from similarly treated patients reported in a recent prospective therapy trial. 14 Standard Protocol Approvals, Registrations, and Patient Consents This study was approved by each university institutional review board with a waiver of consent. No sponsor was involved in funding this study, the study design, the data reporting, or the decision to submit for publication.…”

Section: Methodsmentioning

confidence: 99%

See 4 more Smart Citations

Pulmonary metastases in patients with recurrent, treatment‐resistant meningioma

Alexandru

Glantz

Kim

et al. 2011

Cancer

View full text Add to dashboard Cite

BACKGROUND:Meningioma is the most common extra-axial primary intracranial tumor in adults that rarely metastasizes outside of the central nervous system (CNS). Among recognized sites of metastases, the lung is the most common, but the importance of lung metastases relative to prognosis is unknown. 111 Indium ( 111 In)-octreotide scintigraphy (octreotide scanning) is a valuable imaging modality with which to evaluate intracranial meningiomas and their response to treatment with somatostatin analogues and has the potential to identify extracranial metastatic disease. METHODS: In this retrospective multicenter study, adult patients treated for recurrent meningioma were identified. These patients underwent 111 In-octreotide positron emission tomography/computed tomography imaging (octreotide scintigraphy) and were found to have positive octreotide uptake in their lungs. RESULTS: Six cases were identified with recurrent meningioma (after surgery, radiotherapy, and at least 1 chemotherapy agent) and pulmonary lesions by octreotide scintigraphy. Biopsy of a pulmonary lesion in 1 patient confirmed the diagnosis of metastatic meningioma. Patients with metastatic pulmonary involvement identified by 111 In-octreotide scintigraphy in this case series had an overall survival of 6 months, which is less than that reported from previously published series of patients with unknown systemic disease status. CONCLUSIONS: 111 In-octreotide scintigraphy is useful for assessing both CNS disease and extracranial metastases. The presence of pulmonary metastases appears to negatively affect survival in patients with recurrent meningioma. The usefulness of 111 In-octreotide scintigraphy should be considered in staging patients with recurrent meningioma who are considered for further treatment. A prospective study to confirm this finding is warranted.

show abstract

mentioning

confidence: 80%